AAP Recommends Nirsevimab to Protect Infants Against Severe RSV: Monoclonal Antibody Gains Traction
USA: The American Academy of Pediatrics (AAP) has released recommendations for the use of the monoclonal antibody nirsevimab for the prevention of respiratory syncytial virus (RSV) disease. Nirsevimab was recently approved by the FDA and recommended by the CDC.
The AAP recommends that all infants younger than 8 months receive nirsevimab to prevent severe diseases from respiratory syncytial virus. It is also recommended for infants and children aged 8 through 19 months who are at increased risk of severe RSV disease and entering their second RSV season, including those recommended by the AAP to receive palivizumab.
The recommendation aligns with the CDC's (Centers for Disease Control and Prevention) recommendations for the monoclonal antibody, which were made a few weeks ago.
Nirsevimab received approval from the US FDA (Food and Drug Administration) in July to administer to children during their initial RSV seasons.
These recommendations extend to infants suggested by the AAP to receive the monoclonal antibody palivizumab. Notably, children who receive nirsevimab should not be given palivizumab within the same RSV season.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.